All In MedTech

Device Trial Radar · NCT07802327

PMCF Study of GX-01S CGM in Adults With Diabetes

PROspective Post-Market Clinical Follow-Up (PMCF) Study to Assess the Clinical Benefits of the GX-01S Continuous Glucose Monitoring System in Adult Patients With Diabetes Type 1 and Type 2

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Feb 2028

Study completion Jun 2028

Sponsor

Lead sponsor
MicroTech Medical(Hangzhou)Co.,Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Sep 3, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study evaluates the GX-01S Continuous Glucose Monitoring (CGM) System in adults with Type 1 or Type 2 diabetes. CGM systems measure glucose levels continuously throughout the day, providing real-time information that can help patients manage their diabetes more effectively. The study aims to determine whether using the GX-01S CGM System improves glycemic control, as measured by Time in Range (the percentage of time glucose levels stay within a target range). It will also assess safety, treatment satisfaction, quality of life, and ease of use of the device. Participants will wear the GX-01S CGM System for approximately 135 days (about 4.5 months). The first 15 days will be a "blinded" period where participants cannot see their glucose readings, which will be used to establish a baseline. For the remaining 120 days, participants will have full access to their real-time glucose data. Participants will visit the study site at the beginning, Day 15, Day 45, and Day 135 for assessments and questionnaires. The study will enroll 100 adult patients across multiple centers in Europe. Enrollment is expected to begin in September 2026.

Conditions

  • Diabetes Mellitus
  • Diabetes Mellitus ( Type 1 and Type 2)

Interventions

  • GX-01S Continuous Glucose Monitoring SystemDevice

    The GX-01S CGM System is a single-use, real-time continuous glucose monitoring device designed to provide interstitial glucose readings for the management of diabetes. The system consists of three primary components: (1) a sterile sensor with an integrated applicator, (2) a transmitter for wireless data transfer, and (3) the LinX mobile application for real-time display and alert management. The sensor is designed for a wear life of up to 15 days and provides glucose readings every minute. The system includes customizable alerts for high/low glucose levels and allows for remote data sharing through the Pancares Web Portal.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Time in Range (TIR), Time Above Range (TAR), and Time Below Range (TBR) from Blinded Baseline to Unblinded CGM UseTime frame: 15-day blinded run-in period compared to Day 45 unblinded follow-up visit
  2. Change in Time in Range (TIR), Time Above Range (TAR), and Time Below Range (TBR) from Blinded Baseline to Unblinded CGM UseTime frame: 15-day blinded run-in period (Visit 2 to Visit 3) compared to Day 45 unblinded follow-up visit (Visit 3 to Visit 4)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.